Ameriprise
VTVT icon

Ameriprise’s vTv Therapeutics VTVT Stock Holding History

Ameriprise’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,323
Closed -$1.04M – 3702
2017
Q4 		$1.04M Sell
4,323
-5
-0.1% -$1.12K ﹤0.01% 2960
2017
Q3 		$1.03M Sell
4,328
-2,277
-34% -$454K ﹤0.01% 2946
2017
Q2 		$1.31M Buy
6,605
+2,546
+63% +$531K ﹤0.01% 2809
2017
Q1 		$1.06M Buy
4,059
+2
+0% +$456 ﹤0.01% 2862
2016
Q4 		$784K Buy
4,057
+5
+0.1% +$1.15K ﹤0.01% 3079
2016
Q3 		$1.17M Buy
4,052
+15
+0.4% +$3.61K ﹤0.01% 2854
2016
Q2 		$936K Buy
4,037
+593
+17% +$136K ﹤0.01% 2908
2016
Q1 		$711K Sell
3,444
-4,499
-57% -$1.12M ﹤0.01% 3008
2015
Q4 		$2.16M Sell
7,943
-807
-9% -$226K ﹤0.01% 2560
2015
Q3 		$2.28M Buy
+8,750
New +$3.05M ﹤0.01% 2545

Other funds holding VTVT

GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's VTVT Position: Q1 2018 in Review

Ameriprise sold out of vTv Therapeutics (VTVT) in Q1 2018, closing a stake of 4,323 shares — an estimated $1.04M sold.

Ameriprise first reported a position in VTVT in Q3 2015 and held it in 10 quarters. The position peaked at $2.28M in Q3 2015. 41 funds tracked by Wall St. Rank hold VTVT as of Q1 2018.

  • Ameriprise reported no remaining vTv Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ameriprise sold 4,323 vTv Therapeutics shares in Q1 2018, an estimated $1.04M.
  • Ameriprise first reported a position in vTv Therapeutics in Q3 2015 and held it in 10 quarters.
  • Ameriprise's vTv Therapeutics position peaked at $2.28M in Q3 2015.
  • 41 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2018.

Based on Ameriprise's 13F filing for Q1 2018, filed 15 May 2018.